Evidence map›Paper›PMID 34381091›Full record

ArticleScientific reports2021

A novel bis(pyrazolyl)methane compound as a potential agent against Gram-positive bacteria.

Pedro Seguí, John J Aguilera-Correa, Elena Domínguez-Jurado, Christian M Sánchez-López, Ramón Pérez-Tanoira, Ana V Ocaña, José A Castro-Osma, Jaime Esteban, Antonio Marcilla, Carlos Alonso-Moreno and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. A bis(pyrazolyl)methane derivative against clinicalLaryngoscope investigative otolaryngology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Pedro SeguíDepartment of Otorhinolaryngology, Complejo Hospitalario Universitario, 02006, Albacete, Spain.
John J Aguilera-CorreaClinical Microbiology Department, IIS-Fundacion Jimenez Diaz-UAM, 28040, Madrid, Spain.
Elena Domínguez-JuradoNanoCRIB Unit, Centro Regional de Investigaciones Biomédicas, 02008, Albacete, Spain.
Christian M Sánchez-LópezDepartment of Farmàcia i Tecnologia Farmacèutica i Parasitologia, University of Valencia, Burjassot, 46100, Valencia, Spain.
Ramón Pérez-TanoiraClinical Microbiology Department, Hospital Universitario Príncipe de Asturias, Madrid, Spain.
Ana V OcañaInstituto de Investigación en Discapacidades Neurológicas (IDINE), University of Castilla-La Mancha, 02001, Albacete, Spain.
José A Castro-OsmaNanoCRIB Unit, Centro Regional de Investigaciones Biomédicas, 02008, Albacete, Spain.
Jaime EstebanClinical Microbiology Department, IIS-Fundacion Jimenez Diaz-UAM, 28040, Madrid, Spain.
Antonio MarcillaDepartment of Farmàcia i Tecnologia Farmacèutica i Parasitologia, University of Valencia, Burjassot, 46100, Valencia, Spain.
Carlos Alonso-MorenoNanoCRIB Unit, Centro Regional de Investigaciones Biomédicas, 02008, Albacete, Spain.
Francisco C Pérez-MartínezInstituto de Investigación en Discapacidades Neurológicas (IDINE), University of Castilla-La Mancha, 02001, Albacete, Spain. franciscocarlos.perez@gmail.com.
Milagros Molina-AlarcónInstituto de Investigación en Discapacidades Neurológicas (IDINE), University of Castilla-La Mancha, 02001, Albacete, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was designed to propose alternative therapeutic compounds to fight against bacterial pathogens. Thus, a library of nitrogen-based compounds bis(triazolyl)methane (1T-7T) and bis(pyrazolyl)methane (1P-11P) was synthesised following previously reported methodologies and their antibacterial activity was tested using the collection strains of Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa. Moreover, the novel compound 2P was fully characterized by IR, UV-Vis and NMR spectroscopy. To evaluate antibacterial activity, minimal inhibitory concentrations (MICs), minimal bactericidal concentrations (MBCs), minimum biofilm inhibitory concentrations (MBICs), and minimum biofilm eradication concentrations (MBECs) assays were carried out at different concentrations (2-2000 µg/mL). The MTT assay and Resazurin viability assays were performed in both human liver carcinoma HepG2 and human colorectal adenocarcinoma Caco-2 cell lines at 48 h. Of all the synthesised compounds, 2P had an inhibitory effect on Gram-positive strains, especially against S. aureus. The MIC and MBC of 2P were 62.5 and 2000 µg/mL against S. aureus, and 250 and 2000 µg/mL against E. faecalis, respectively. However, these values were > 2000 µg/mL against E. coli and P. aeruginosa. In addition, the MBICs and MBECs of 2P against S. aureus were 125 and > 2000 µg/mL, respectively, whereas these values were > 2000 µg/mL against E. faecalis, E. coli, and P. aeruginosa. On the other hand, concentrations up to 250 µg/mL of 2P were non-toxic doses for eukaryotic cell cultures. Thus, according to the obtained results, the 2P nitrogen-based compound showed a promising anti-Gram-positive effect (especially against S. aureus) both on planktonic state and biofilm, at non-toxic concentrations.

Indexed as

Anti-Bacterial AgentsBiofilmsCaco-2 CellsCell Line, TumorGram-Positive BacteriaHep G2 CellsHumansMethaneMicrobial Sensitivity TestsAnti-Bacterial AgentsMethane

Identifiers

PMID34381091
PMCPMC8357914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.